Cisplatin

June 8, 2020June 8, 2020

Merck to Launch Ontruzant, a Herceptin Biosimilar, in US

News

Ontruzant (trastuzumab-dttb), a biosimilar to Genentech‘s Herceptin (trastuzumab), will now be made available in the U.S. as a treatment for HER2-overexpressing breast cancers as well as for stomach cancers, according to a ... Read more

March 13, 2020March 13, 2020

Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds

News

Women with newly diagnosed breast cancer who carry a mutation in their BRCA genes may continue to receive the standard pre-surgery chemotherapy regimen used for other breast cancer patients, according ... Read more

September 20, 2019September 20, 2019

FDA OKs Use of Tool to Predict Patient Response to New Form of Cisplatin in Planned Phase 3 Study

News

The U.S. Food and Drug Administration (FDA) has approved use of a device, called LiPlaCis DRP, that works to predict response to the next-generation investigational chemotherapy LiPlaCis in a planned Phase 3 ... Read more

February 9, 2018February 9, 2018

7 in 10 Metastatic Breast Cancer Patients Benefit from LiPlaCis, Early Trial Data Shows

News

A targeted liposomal formulation of the chemotherapy treatment cisplatin, called LiPlaCis, induced clinical benefit in 70 percent of breast cancer patients included in a Phase 1/2 trial. The clinical response, however, ... Read more

October 27, 2017

LiPlaCis Shows Promise in Phase 2 Part of Trial Dealing with Hard to Treat Breast Cancer

News

Three of five patients with breast cancer that had spread to other organs responded to Oncology Ventures’ LiPlaCis or had their disease become stable with it, according to early results of the ... Read more